Long-acting injectable naltrexone for the management of patients with opioid dependence

Substance Abuse: Research and Treatment

Volumn 5, Issue 1, 2011, Pages 1-9

  Kjome, Kimberly L ^a   Gerard Moeller, F ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Heroin; Naltrexone; Opioid; Opioid dependence; Vivitrol

Indexed keywords

BUPRENORPHINE; DEPOTREX; LONG ACTING DRUG; METHADONE; NALOXONE; NALTREXONE; PLACEBO; UNCLASSIFIED DRUG;

ABSCESS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL EVALUATION; DEPRESSION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; IMPLANT; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; LIVER TOXICITY; LOEFFLER PNEUMONIA; NAUSEA; NECROSIS; OPIATE ADDICTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; SUICIDAL BEHAVIOR; SUSTAINED RELEASE FORMULATION; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WITHDRAWAL SYNDROME;

EID: 79952970069     PISSN: None     EISSN: 11782218     Source Type: Journal    
DOI: 10.4137/SART.S5452     Document Type: Review

References (50)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (Revised 4th ed). Washington, DC; 2000.
2. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28:321-9.
3. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1:13-20.
4. Administration SAaMHS. Results from the 2007 National Survey of Drug Use and Health: National Findings. Rockville, MD: 2008.
5. Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med. 1969; 280:1372-5.
6. Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand. 1990;82:223-7.
7. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2:485-8.
8. Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther. 1995;274:361-72.
9. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569-80.
10. Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006;101:491-503.
11. Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988;35:192-213.
12. Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci. 2007;9:455-70.
13. Navaratnam V, Jamaludin A, Raman N, Mohamed M, Mansor SM. Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts. Drug Alcohol Depend. 1994;34:231-6.
14. Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, et al. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol. 2006;26:610-25.
15. Licko V. Overview of human pharmacokinetics of naltrexone. NIDA Res Monogr. 1981;28:161-71.
16. Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. 2010 Oct;12(5):448-53.
17. Rawson RA, Glazer M, Callahan EJ, Liberman RP. Naltrexone and behavior therapy for heroin addiction. NIDA Res Monogr. 1979:26-43.
18. Kleber HD. Clinical aspects of the use of narcotic antagonists: the state of the art. Int J Addict. 1977;12:857-61.
19. Shufman EN, Porat S, Witztum E, Gandacu D, Bar-Hamburger R, Ginath Y. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry. 1994;35:935-45.
20. O'Brien CP, Greenstein RA, Mintz J, Woody GE. Clinical experience with naltrexone. Am J Drug Alcohol Abuse. 1975;2:365-77.
21. Fram DH, Marmo J, Holden R. Naltrexone treatment-the problem of patient acceptance. J Subst Abuse Treat. 1989;6:119-22.
22. Kleber HD, Kosten TR. Naltrexone induction: psychologic and pharmacologic strategies. J Clin Psychiatry. 1984;45:29-38.
23. Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 1999;54:127-35.
24. Resnick RB, Schuyten-Resnick E, Washton AM. Narcotic antagonists in the treatment of opioid dependence: review and commentary. Compr Psychiatry. 1979;20:116-25.
25. Rothenberg JL, Sullivan MA, Church SH, Seracini A, Collins E, Kleber HD, et al. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat. 2002;23:351-60.
26. Sullivan MA, Rothenberg JL, Vosburg SK, et al. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am J Addict. 2006;15(2):150-9.
27. Sullivan MA, Garawi F, Bisaga A, Comer SD, Carpenter K, Raby WN, et al. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend. 2007;91:289-92.
28. Tennant FS, Rawson RA, Cohen AJ, Mann A. Clinical experience with naltrexone in suburban opioid addicts. The Journal of Clinical Psychiatry. 1984 Sep;45(9 Pt 2):42-5.
29. Greenstein RA, O'Brien CP, McLellan AT, Woody GE, Grabowski J, Long M, et al. Naltrexone: a short term treatment for opiate dependence. Am J Drug Alcohol Abuse. 1981;8:291-300.
30. Preston KL, Silverman K, Umbricht A, De Jesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 1999;1;54(2):127-35.
31. Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse. 2006;32(4): 503-17.
32. Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy. 2007;2:35.
33. Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. 2009;12:448-53.
34. Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009;66:1108-15.
35. Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res. 2006;30:480-90.
36. Dunbar JL, Turncliff RZ, Hayes SC, Farrell CB. Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. J Stud Alcohol Drugs. 2007;68:862-70.
37. Farid WO, Dunlop SA, Tait RJ, Hulse GK. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol. 2008;6:125-50.
38. Brewer C. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases. Addict Biol. 2002;7:321-3.
39. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot naltrexone: long lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl). 2002;159:351-60.
40. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al. Injectable, sustained release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63: 210-8.
41. Brooks AC, Comer SD, Sullivan MA, Bisaga A, Carpenter KM, Raby WM, et al. Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment. J Clin Psychiatry. 2010.
42. Fishman MJ, Winstanley EL, Curran E, Garrett S, Subramaniam G. Treatment of opioid dependence in adolescents and young adults with extended-release naltrexone: preliminary case series and feasibility. Addiction. 2010;105(9):1669-76.
43. Krupitsky EM, Illeperuma A, Gastfriend DR, Silverman DL. Efficacy and safety of extended-release naltrexone (XR-NTX) for the treatment of opioid dependence. Presented at College on Problems of Drug Dependence (CPDD), Scottsdale AZ, 2010.
44. Yen MH, Ko HC, Tang FI, Lu RB, Hong JS. Study of hepatotoxicity of naltrexone in the treatment of alcoholism. Alcohol. 2006;38:117-20.
45. Lucey MR, Silverman BL, Illeperuma A, O'Brien CP. Hepatic safety of once-monthly injectable extended release naltrexone administered to actively drinking alcoholics. Alcohol Clin Exp Res. 2008;32:498-504.
46. Brewer C, Wong VS. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addict Biol. 2004;9:81-7.
47. Verebey K, Mule SJ. Naltrexone pharmacology, pharmacokinetics, and metabolism: current status. Am J Drug Alcohol Abuse. 1975;2:357-63.
48. Digiusto E, Shakeshaft A, Ritter A, O'Brien S, Mattick RP. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction. 2004;99:450-60.
49. BC. Opioid antagonist-induced upregulation and functional supersensitivity. Rev Clin Basic Pharm. 1988;7:109-28.
50. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009 Aug;10(11):172-40.